| Literature DB >> 28060740 |
Weidong Liu1, Li Mao2, Feng Ji1, Fengli Chen3, Yuedong Hao1, Gang Liu1.
Abstract
GSK621 is a novel AMP-activated protein kinase (AMPK) activator. This study tested its potential cytoprotective effect in hydrogen peroxide (H2O2)-treated osteoblasts. In cultured MC3T3-E1 osteoblastic cells and primary murine osteoblasts, GSK621 significantly attenuated H2O2-induced cell death and apoptosis. AMPK activation was required for GSK621-induced osteoblast cytoprotection. Inhibition of AMPK, by AMPKα1 T172A mutation or shRNA silence, almost completely blocked GSK621-induced osteoblast cytoprotection. Reversely, introduction of a constitutively-active AMPKα1 (T172D) alleviated H2O2 injuries in MC3T3-E1 cells. Further, GSK621 increased nicotinamide adenine dinucleotide phosphate (NADPH) content in osteoblasts to inhibit H2O2-induced reactive oxygen species (ROS) production. Meanwhile, GSK621 activated cytoprotective autophagy in the osteoblasts. On the other hand, pharmacological inhibition of autophagy alleviated GSK621-mediated osteoblast cytoprotection against H2O2. These results suggest that targeted activation of AMPK by GSK621 ameliorates H2O2-induced osteoblast cell injuries.Entities:
Keywords: AMPK; GSK621; osteoblasts; osteonecrosis; oxidative stress
Mesh:
Substances:
Year: 2017 PMID: 28060740 PMCID: PMC5354679 DOI: 10.18632/oncotarget.14454
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553